Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.60 |
| ▸ | CDK2 | P24941 | 3/20 | 0.60 |
| ▸ | JAK2 | O60674 | 1/20 | 0.60 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.60 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.60 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.60 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.60 |
| ▸ | ZAP70 | P43403 | 9/20 | 0.56 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.56 |
| ▸ | PRKCG | P05129 | 3/20 | 0.56 |
| ▸ | PRKCB | P05771 | 3/20 | 0.56 |
| ▸ | LCK | P06239 | 3/20 | 0.56 |
| ▸ | PRKCA | P17252 | 3/20 | 0.56 |
| ▸ | PRKCH | P24723 | 3/20 | 0.56 |
| ▸ | PRKCI | P41743 | 3/20 | 0.56 |
| ▸ | PRKCE | Q02156 | 3/20 | 0.56 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.56 |
| ▸ | PRKCZ | Q05513 | 3/20 | 0.56 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.56 |
| ▸ | PRKD1 | Q15139 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1667266 | 0.92 | EGFR (0.67) | EGFRCDK2JAK2PIK3CAPIK3CB | |
| SCHEMBL1667591 | 0.91 | MEN1 (0.50) | EGFRCDK2JAK2PIK3CAPIK3CB | |
| SCHEMBL12274588 | 0.89 | MEN1 (0.53) | EGFRCDK2JAK2PIK3CAPIK3CB | |
| SCHEMBL1667038 | 0.85 | EGFR (0.58) | EGFRCDK2JAK2PIK3CAPIK3CB | |
| SCHEMBL1667135 | 0.85 | CDK2 (0.66) | EGFRCDK2JAK2PIK3CAPIK3CB | |
| SCHEMBL1667125 | 0.83 | EGFR (0.55) | EGFRCDK2JAK2PIK3CAPIK3CB | |
| SCHEMBL12276011 | 0.82 | MEN1 (0.56) | EGFRCDK2JAK2PIK3CAPIK3CB | |
| SCHEMBL12274953 | 0.81 | EGFR (0.53) | EGFRCDK2JAK2PIK3CAPIK3CB | |
| SCHEMBL4360382 | 0.81 | EGFR (0.73) | EGFRCDK2JAK2PIK3CAPIK3CB | |
| SCHEMBL1667656 | 0.81 | TBK1 (0.76) | TBK1IKBKE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238540-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1 | MYREXIS, INC. (US) | 2012-09-20 | — | — | US | claimed |
| EP-2488503-A1 | AMINO - PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBKL AND/OR IKK EPSILON | Myrexis, Inc. (US) | 2012-08-22 | — | — | EP | claimed |
| WO-2011046970-A1 | AMINO - PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBKL AND/OR IKK EPSILON | MYREXIS, INC. (US) | 2011-04-21 | — | — | WO | claimed |
| US-20150352108-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBK1 AND/OR IKK EPSILON | ALZHEIMER'S INSTITUTE OF AMERICA (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150352108-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBK1 AND/OR IKK EPSILON | ALZHEIMER'S INSTITUTE OF AMERICA (US) | 2015-12-10 | — | — | US | disclosed |
| US-20120238540-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1 | MYREXIS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120238540-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1 | MYREXIS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| EP-2488503-A1 | AMINO - PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBKL AND/OR IKK EPSILON | Myrexis, Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| WO-2011046970-A1 | AMINO - PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBKL AND/OR IKK EPSILON | MYREXIS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011046970-A1 | AMINO - PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBKL AND/OR IKK EPSILON | MYREXIS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150352108-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBK1 AND/OR IKK EPSILON | TBK1, NFKBIA, CHUK | EGFR 3542/4885CDK2 184/4885JAK2 1160/4885 |
| US-20120238540-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1 | TBK1, NFKBIA, IKBKB | EGFR 2535/4885CDK2 122/4885JAK2 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.